tiprankstipranks
Trending News
More News >
Modus Therapeutics Holding AB (DE:99Z)
FRANKFURT:99Z

Modus Therapeutics Holding AB (99Z) Price & Analysis

Compare
0 Followers

99Z Stock Chart & Stats


Financials

99Z FAQ

What was Modus Therapeutics Holding AB’s price range in the past 12 months?
Modus Therapeutics Holding AB lowest stock price was €0.09 and its highest was €0.19 in the past 12 months.
    What is Modus Therapeutics Holding AB’s market cap?
    Modus Therapeutics Holding AB’s market cap is €4.66M.
      When is Modus Therapeutics Holding AB’s upcoming earnings report date?
      Modus Therapeutics Holding AB’s upcoming earnings report date is Aug 27, 2025 which is in 82 days.
        How were Modus Therapeutics Holding AB’s earnings last quarter?
        Modus Therapeutics Holding AB released its earnings results on May 14, 2025. The company reported -€0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.007.
          Is Modus Therapeutics Holding AB overvalued?
          According to Wall Street analysts Modus Therapeutics Holding AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Modus Therapeutics Holding AB pay dividends?
            Modus Therapeutics Holding AB does not currently pay dividends.
            What is Modus Therapeutics Holding AB’s EPS estimate?
            Modus Therapeutics Holding AB’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Modus Therapeutics Holding AB have?
            Modus Therapeutics Holding AB has 35,938,900 shares outstanding.
              What happened to Modus Therapeutics Holding AB’s price movement after its last earnings report?
              Modus Therapeutics Holding AB reported an EPS of -€0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -8.333%.
                Which hedge fund is a major shareholder of Modus Therapeutics Holding AB?
                Currently, no hedge funds are holding shares in DE:99Z

                Company Description

                Modus Therapeutics Holding AB

                Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. Its lead product is Sevuparin, a polysaccharide to treat patients with sepsis and septic shock, which is under Phase Ib clinical study. The company was founded in 2011 and is headquartered in Stockholm, Sweden.
                Similar Stocks
                Company
                Price & Change
                Follow
                Stayble Therapeutics AB
                ExpreS2ion Biotech Holding AB
                Spago Nanomedical AB
                CombiGene AB
                Sprint Bioscience AB
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis